Egrifta (Tesamorelin) and Sexual Function: What Women Need to Know

What Tesamorelin Actually Does in the Body

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary, stimulating pulsatile growth hormone (GH) release, which in turn raises insulin-like growth factor 1 (IGF-1). That two-step cascade is what makes its effects on sexual function indirect but real.

In the landmark Falutz et al. Trial published in NEJM 2007, 412 HIV-positive adults on antiretroviral therapy received either tesamorelin 2 mg/day or placebo for 26 weeks. Visceral adipose tissue fell by approximately 15% in the treated group, measured by CT scan, compared with minimal change on placebo. IGF-1 levels rose significantly. Body-composition improvements were accompanied by self-reported quality-of-life gains, a finding that matters enormously for sexual self-perception.

The GH-IGF-1 Axis and Female Sexual Physiology

GH and IGF-1 are not exclusively metabolic hormones. Vaginal tissue, clitoral erectile tissue, and labial skin all carry IGF-1 receptors, and local IGF-1 signaling supports nitric-oxide synthesis, tissue perfusion, and lubrication. In women with low GH output, whether from pituitary disease, aging, or the metabolic disruption of HIV, those tissues can thin and dry in ways that overlap clinically with genitourinary syndrome of menopause (GSM).

How HIV Lipodystrophy Specifically Disrupts Sexual Wellbeing

HIV-associated lipodystrophy involves visceral fat accumulation in the abdomen, dorsocervical fat ("buffalo hump"), and peripheral fat loss in the face, buttocks, and limbs. For women, visible facial lipoatrophy and truncal obesity alter body image in ways that are documented to reduce sexual confidence and intimacy. Reducing visceral fat with tesamorelin addresses one of those drivers directly.

Sex-Specific Pharmacology: How Women Process Tesamorelin Differently

Women handle the GH axis differently from men, and that difference shapes both the benefits and risks of tesamorelin.

Baseline GH Secretion Is Already Sex-Differentiated

Women of reproductive age secrete GH in higher amplitude pulses than age-matched men, partly because estrogen amplifies pituitary GH release. This means premenopausal women on tesamorelin may reach IGF-1 targets at lower effective stimulation than men, while postmenopausal women, who have lost that estrogen amplification, may need more stimulation to see the same IGF-1 response.

Estrogen Status Changes the Response

Oral estrogen (including combined oral contraceptives) blunts hepatic IGF-1 generation despite adequate GH secretion, a well-characterized pharmacokinetic interaction. If you are taking an oral estrogen-containing contraceptive or oral hormone therapy while on tesamorelin, your IGF-1 rise may be attenuated. Transdermal estrogen does not carry the same hepatic first-pass effect and is less likely to suppress IGF-1.

Insulin Sensitivity and Glucose

Tesamorelin raises fasting glucose in some patients. Women with polycystic ovary syndrome (PCOS) already carry baseline insulin resistance, and the glucose-elevating potential of GH stimulation is an additional risk worth discussing with your clinician before starting.

Tesamorelin and Sexual Function: The Evidence (and the Gaps)

Sexual function was not a pre-specified primary endpoint in the key tesamorelin trials. That omission reflects a broader pattern in HIV drug development, where most early participants were men.

The table below maps the plausible mechanistic pathways from tesamorelin to sexual function in women, categorized by evidence quality.

| Pathway | Mechanism | Evidence Quality | |---|---|---| | Visceral fat reduction | Improves body image, reduces abdominal pressure, may ease dyspareunia from positional discomfort | Indirect (body image data from Falutz NEJM 2007) | | IGF-1 rise | Supports vaginal and clitoral tissue perfusion via nitric oxide | Mechanistic (receptor data); no RCT in women specifically | | Cortisol reduction | GH stimulation may modestly reduce hypercortisolemia of chronic HIV/ART stress | Mechanistic; limited human data | | Improved insulin sensitivity | Reduces SHBG suppression, may free more bioavailable testosterone | Plausible extrapolation | | Reduced psychological burden of lipodystrophy | Improved self-image linked to sexual confidence | Observational, quality-of-life sub-analyses |

The honest takeaway: no randomized controlled trial has measured a validated female sexual function scale (such as the Female Sexual Function Index, FSFI) as a primary outcome for tesamorelin. Women's sexual health data is extrapolated from metabolic endpoints and biological plausibility, not from direct measurement. WomanRx considers this gap a clinical priority, and any prescriber who tells you sexual function improvement is a guaranteed outcome is overstating the evidence.

What the Quality-of-Life Data Shows

The Falutz et al. 2007 trial included a quality-of-life sub-analysis using the LDQOL (Lipodystrophy Quality of Life) instrument. Participants on tesamorelin reported improvements in self-perceived physical appearance and worry about appearance, both of which correlate with sexual confidence in subsequent analyses of HIV-positive cohorts. A 2010 Phase 3 extension trial by Falutz et al. confirmed durable visceral fat reduction at 52 weeks and sustained quality-of-life improvements, though sexual function was not broken out by sex.

Body Image and Libido Are Directly Connected

A systematic review published in the Journal of Sexual Medicine found that body image dissatisfaction is one of the strongest independent predictors of reduced sexual desire and arousal in women with chronic illness. HIV-related lipodystrophy generates exactly that dissatisfaction. Tesamorelin's 15% visceral fat reduction in the Falutz NEJM trial is large enough to produce visible abdominal change in many patients, and visible change affects how a woman feels in her body.

Life-Stage Differences: Reproductive Years Through Postmenopause

Reproductive Years (Ages 18-40)

During reproductive years, the GH axis operates near its lifetime peak. Adding tesamorelin on top of normal GH pulsatility risks IGF-1 overshoot. Monthly IGF-1 monitoring is standard practice; if levels exceed the age-normalized upper limit, dose reduction or temporary interruption is warranted. Elevated IGF-1 carries theoretical concerns about hormone-sensitive tissue stimulation, although causality with breast cancer specifically has not been established in short-term tesamorelin use.

Sexual function in this age group is most often affected by lipodystrophy-driven body image issues and ART-related fatigue rather than by intrinsic GH deficiency. Tesamorelin addresses the first mechanism directly.

Perimenopause (Typically Ages 40-52)

This is where the clinical picture becomes most nuanced. Perimenopause involves:

• Declining estrogen, which reduces the estrogen-amplified GH pulses described above
• Rising FSH and LH instability
• Independent risk of sexual dysfunction from vaginal dryness, mood changes, and sleep disruption
• A potential GH-axis decline that overlaps with menopausal transition

Women with HIV who enter perimenopause may do so up to 5 years earlier than HIV-negative peers, meaning this life stage is particularly relevant for this population. Tesamorelin's ability to restore some GH-axis drive during a period of natural GH decline is mechanistically appealing. No published trial has enrolled perimenopausal women with HIV specifically to test sexual outcomes. The evidence gap is real and should be disclosed.

Postmenopause

Postmenopausal women have lower basal IGF-1, less GH pulsatility, and no endogenous estrogen amplification of GH release. The Falutz trials did not stratify results by menopausal status. If you are postmenopausal and on oral estrogen-based hormone therapy, the hepatic IGF-1 suppression effect described earlier means your clinician may need to adjust IGF-1 targets or consider transdermal estrogen instead.

Sexual symptoms in this group include GSM (vaginal dryness, dyspareunia, urinary urgency) driven by estrogen loss. Tesamorelin does not replace estrogen. Local vaginal estrogen or ospemifene remains the first-line treatment for GSM, and tesamorelin is not a substitute.

Relevant Female Conditions This Drug Touches

PCOS

Women with PCOS have altered GH secretion patterns, often with blunted GH pulses but elevated IGF-1 bioavailability due to lower IGFBP-3. Tesamorelin's stimulation of additional GH release in a system already prone to IGF-1 excess requires careful monitoring. Insulin resistance in PCOS also compounds the glucose risk.

Female Pattern Hair Loss

GH and IGF-1 support hair follicle cycling. Women with GH deficiency can lose hair density. Whether tesamorelin-driven IGF-1 restoration improves hair in HIV-positive women with lipodystrophy has not been studied, but the mechanistic basis exists.

Hormonal Acne

Rising IGF-1 stimulates sebaceous gland activity. If you are prone to hormonal acne, tesamorelin-driven IGF-1 elevation may worsen it, particularly in reproductive-age women.

Osteoporosis

HIV, ART (especially tenofovir-based regimens), and chronic inflammation reduce bone density. GH and IGF-1 both support bone formation. A secondary analysis of HIV bone data suggests GH-axis improvement may benefit bone, though no tesamorelin-specific bone density RCT in women exists.

Pregnancy, Lactation, and Contraception

Tesamorelin is contraindicated in pregnancy. Stop the drug before attempting conception.

Pregnancy Risk

Tesamorelin is classified as FDA Pregnancy Category X. Animal studies showed fetal harm at doses producing systemic GH-axis stimulation. No adequate human pregnancy data exists, and the potential fetal risk is judged to outweigh any benefit. Because HIV-positive women of reproductive age have every reason to plan pregnancies carefully, discuss tesamorelin's contraindication clearly with your prescriber before starting.

Contraception Requirement

Because tesamorelin is a Category X teratogen, you must use reliable contraception throughout treatment. Long-acting reversible contraception (copper IUD or hormonal IUD) avoids the oral estrogen-IGF-1 interaction problem. If you use combined oral contraceptives, your IGF-1 response to tesamorelin will be blunted by hepatic first-pass estrogen effects. Discuss method choice with your clinician.

Lactation

Tesamorelin's transfer into human breast milk has not been studied. The FDA labeling advises avoiding use during breastfeeding. Women with HIV in high-income settings are generally advised to avoid breastfeeding due to HIV transmission risk, which makes this a concurrent rather than separate decision. Outside high-income settings, the WHO infant feeding guidance for women with HIV on suppressive ART is evolving; consult your infectious disease provider.

Postpartum Considerations

Postpartum GH axis dynamics are not well characterized in HIV-positive women. Tesamorelin should not be restarted until breastfeeding has fully ceased and a clinician has confirmed the drug is appropriate again.

Who This Drug Is Right For, and Who It Is Not

Good Candidates

• Women with documented HIV-associated lipodystrophy (confirmed visceral fat excess by CT or MRI)
• On stable antiretroviral therapy with undetectable or low viral load
• Not pregnant and using reliable contraception
• Baseline IGF-1 within normal range for age and sex (room to stimulate)
• Without active malignancy or personal history of hormone-sensitive cancer

Use With Extra Caution

• Perimenopausal women on oral estrogen (blunted IGF-1 response; consider transdermal)
• Women with PCOS and baseline insulin resistance
• Women prone to hormonal acne (IGF-1-driven sebaceous stimulation)
• Women with pre-diabetes or type 2 diabetes (monitor glucose closely)

Not Appropriate

• Pregnant women or those planning pregnancy without stopping the drug first
• Women with active malignancy
• Women without confirmed HIV-associated lipodystrophy (off-label use for general weight loss or body composition is not supported by current evidence)
• Women with hypersensitivity to GHRH or tesamorelin components

How to Monitor If You Start Tesamorelin

Monitoring is not optional. The following labs matter for women specifically:

At baseline:

• Fasting glucose and HbA1c
• IGF-1 (sex- and age-adjusted reference range)
• Lipid panel (visceral fat change affects triglycerides)
• Liver function (oral estrogen co-use makes hepatic monitoring more relevant)

At 3 months:

• IGF-1 (adjust dose if above upper limit of normal for age and sex)
• Fasting glucose
• Clinical assessment of lipodystrophy change (waist circumference, patient-reported body image)

At 6 months and annually:

• Repeat the above
• Formal CT or MRI measurement if response is uncertain clinically
• Reassess the continuing indication. The Falutz 2010 extension data showed visceral fat returns toward baseline within 6 to 12 weeks of stopping, so this is a continuous, not curative, treatment.

Practical Notes on Injection and Side Effects Women Report

Tesamorelin is injected subcutaneously into the abdomen once daily. Rotation of injection sites matters; women with lipodystrophy may have limited subcutaneous fat at some sites, which affects absorption.

Common side effects reported in clinical trials include injection-site reactions (erythema, pruritus, pain), peripheral edema, and arthralgias. A smaller proportion of users experience glucose elevation severe enough to require intervention.

Women specifically report body-image distress related to the injection site itself in areas of lipoatrophy. Working with a nurse practitioner or clinical pharmacist on technique and site selection reduces this burden.

One side effect rarely mentioned in general sources: some women on GH-axis stimulation report temporary increased water retention premenstrually, as GH and aldosterone interact. This is not dangerous but can be uncomfortable. Tracking your cycle alongside your tesamorelin side-effect diary helps identify whether bloating is cycle-driven or drug-driven.

Egrifta Clinical Update: What Has Changed Since the 2007 Trial

The original Falutz NEJM 2007 publication enrolled predominantly men. Since then:

• A 2014 FDA label update added detailed glucose monitoring requirements after post-marketing surveillance identified clinically meaningful glucose elevation in a subset of users.
• Theratechnologies reformulated Egrifta as Egrifta SV (a stabilized formulation), reducing daily injection volume and improving patient adherence per company-reported post-marketing data.
• No adequately powered RCT has yet enrolled women-only cohorts or stratified sexual function by sex and menopausal status. This remains the most important evidence gap for women using this drug.
• A 2022 review in the Journal of the International AIDS Society acknowledged that women with HIV are underrepresented in lipodystrophy research and called for sex-stratified analyses in future trials.